TandemAI’s revolutionary platform seamlessly combines the power of our proprietary algorithms driven by physics-based and AI approaches with wet lab experimentation into a workspace tailored for user-friendly collaboration and fully integrated drug discovery.

TandemAI is a pioneering technology company with a dedicated mission to transform global drug discovery with advanced AI and physics-based technologies while making it accessible to all. We seamlessly integrate cutting-edge AI-driven technologies and …

Mar 1, 2023 · TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven and physics-based high performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with...

Discover how our AI-powered mobile apps can transform the way you engage with your customers and manage your business. We are dedicated to leveraging the latest advancements in AI to drive innovation and success for our clients. Who are Tandem AI? We are a group of developers that are integrating AI into the mobile app space.

Mar 1, 2023 · TandemAI, with offices in New York, San Diego and China, has built its networked platform from the ground up in China to increase the speed of drug discovery and deliver cost-effective ...

Developer of an advanced network platform designed to lower barriers to entry to the most advanced tools in drug discovery.

Leverage industry-leading tools, including FEP and small molecule generative AI methods for integrated drug discovery. Access all our tools and services, and collaborate with both your own team and our team of experts in one user-friendly, cloud-based workspace.

TandemAI, a technology company focused on transforming drug discovery infrastructure, announced it has raised $35 million in a Series A financing to expand its drug discovery service platform that integrates breakthrough computational tools with wet lab biophysics, medicinal chemistry, and biology.

Suzhou TandemAI, a drug discovery company, closed a $35 million Series A round to expand its platform that integrates breakthrough computational tools with wet lab biophysics, medicinal chemistry and biology.